New drugs study findings have been reported by researchers at State University of New Jersey, Department of Pharmaceutics
2007 NOV 19 -- Scientists discuss in 'Peritoneal macrophage uptake, pharmacokinetics and biodistribution of macrophage-targeted PEG-fMLF (N-formyl-methionyl-leucyl-phenylalanine) nanocarriers for improving HIV drug delivery' new findings in drugs. In this recently published article, scientists in the United States conducted a study "To assess in vivo macrophage targeting potential of PEG-fMLF nanocarriers and to investigate their biodistribution, peritoneal macrophage uptake, and pharmacokinetics Multiple copies of fMLF were conjugated to purchased and novel (branched, peptide-based) PEG nanocarriers. Peritoneal macrophage uptake was evaluated in mice 4 hours after IP administration of fluorescence-labeled PEG-fMLF nanocarriers." "Pharmacokinetics and biodistribution were determined in rats after IV administration of tritiated PEG-fMLF nanocarriers Attachment of one, two, or four fMLF copies increased uptake in macrophages by 3.8-, 11.3-, and 23.6-fold compared to PEG without fMLF. Pharmacokinetic properties and tissue distribution also differed between nanocarriers with and without fMLF. Attachment of fMLF residues increased the t(1/2) of PEG(5K) by threefold but decreased the t(1/2) of PEG(20K) by 40%. Attachment of fMLF increased accumulation of nanocarriers into macrophages of liver, kidneys and spleen. However, on a molar basis, penetration was equivalent suggesting nanocarrier size and targeting moieties are important determinants These results demonstrate the feasibility for targeting macrophages, a primary HIV reservoir site," wrote L. Wan and colleagues, State University of New Jersey, Department of Pharmaceutics. The researchers concluded: "However, these studies also suggest that balancing peripheral tissue penetration (a size-dependent phenomenon) versus target cell uptake specificity remains a challenge to overcome." Wan and colleagues published their study in Pharmaceutical Research (Peritoneal macrophage uptake, pharmacokinetics and biodistribution of macrophage-targeted PEG-fMLF (N-formyl-methionyl-leucyl-phenylalanine) nanocarriers for improving HIV drug delivery. Pharmaceutical Research, 2007;24(11):2110-9). For additional information, contact L. Wan, The State University of New Jersey, Dept. of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers, 160 Frelinghuysen Road, Piscataway, New Jersey 08854 USA.. The publisher's contact information for the journal Pharmaceutical Research is: Kluwer Academic, Plenum Publ, 233 Spring St., New York, NY 10013, USA. Keywords: United States, Piscataway, AIDS, Acquired Immunodeficiency Syndrome, Biotechnology, Drug Delivery, Drugs, HIV, Human Immunodeficiency Virus, Micro-Electro Mechanical Systems (MEMS), Nanopowder Catalysts, Nanotechnology, Pharmaceuticals, Pharmacokinetics, Therapies, Virology. This article was prepared by AIDS Weekly editors from staff and other reports. Copyright 2007, AIDS Weekly via NewsRx.com.
|
